Sarepta Therapeutics, Inc. - Common Stock — Cash Flow (NASDAQ:SRPT) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities 107.47 M-443.17 M-325.35 M-500.99 M-205.79 M-205.48 M 175.28 M Cash from investing activities -121.72 M495.41 M-1.05 B-165.8 M755.56 M69.64 M 226.43 M Cash from financing activities 682.32 M561.57 M232.51 M125 M124.81 M-168.34 M -180.57 M Free cash flow 107.47 M-443.17 M-325.35 M-500.99 M-205.79 M-205.48 M 175.28 M

News

SRPT or PRTA: Which Is the Better Value Stock Right Now?

Sarepta: Caution Still Warranted Despite FDA's Gene Therapy Friendly Stance (NASDAQ:SRPT)

All You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to Buy

SRPT vs. ARGX: Which Stock Is the Better Value Option?

Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?

KROS Turns to Next Wave of TGF-Beta Muscle Therapies

KROS Turns to Next Wave of TGF-Beta Muscle Therapies

Should You Buy KROS After Q1 Miss and Takeda Deal Reset?

Should You Buy KROS After Q1 Miss and Takeda Deal Reset?

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026

Stock Market Soars On Tumbling Oil Prices, Strong Earnings: Weekly Review